CSI Market
Sign In | Register

Epizyme (EPZM) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access EPZM Annual Cash Flow →
This page allows investors to follow Epizyme's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2022)
6 Months 		(Mar 31 2022) (Dec 31 2021) (Sep 30 2021) (Jun 30 2021)
Operating Activities
Income-91.25
Depreciation & amortization2.58
Amortization of Other Assets0.42
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-1.84
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation9.74
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Increase Decrease In Contract With Customer Liability-11.50
Increase Decrease In Operating Lease Assets1.93
Change In Fair Value Of Warrant Liability-1.35
Non Cash Royalty Revenue Related To Sale Of Future Royalty-0.07
Non Cash Interest Expense Related To Sale Of Royalties0.75
Income taxes0.00
Unrealized Gain (Loss) on Investments0.00
Increase (Decrease) in Accounts Receivable-4.64
Increase (Decrease) in Accounts Payable-5.27
Increase (Decrease) in Accrued Liabilities-6.41
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-5.70
Other Working Capital0.09
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.50
Discontinued operations0.00
Net Cash flow from Operating Activities-114.00
Investing Activities
Capital Expenditures-0.01
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities101.95
Payments to Acquire Available-for-sale Securities, Debt-97.42
Real Estate Investments0.00
Payments To Acquire Research And Development In Process-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities4.52
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock82.21
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Reimbursement Of Public Offering Costs-
Payments Of Temporary Equity Issuance Costs-
Proceeds From Issuance Of Common Stock Warrants And Sale Of Royalties-
Proceeds From Issuance Of Common Stock In Connection With Exercise Of Proceeds From Put Option Net Of Financing Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities82.21
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-114.01
Total Cash Flow-27.27
4 historic quarters locked

Sign in to unlock the full Epizyme cash flow history.

Sign In Create Free Account

About Epizyme Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-22-015748

Figures are derived from filed reports and may be restated. Historical data is subject to revision.